TSC-200-A0201

N/A

Report date: 2023/08/04 19:31:04

Base Information

Drug NameTSC-200-A0201
Drug Alias NameTSC-200-A0201TSC-200-A-0201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursPenile NeoplasmsVulvar Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTScan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTScan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursPenile NeoplasmsVulvar Neoplasms +[16] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A